---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018687"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:13:59.574902+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Evofem shareholders reject merger with Aditxt; merger terminated

## Summary
- Shareholders voted against merger: 93.2M for, 7.2M against; proposal not approved at Special Meeting on Oct 20, 2025.
- Evofem terminates Merger Agreement with Aditxt effective Oct 20, 2025; no termination fee paid.
- Company pivots to seek national stock listing and growth capital, targeting sustainable positive EBITDA in 2027.
- CEO states collaboration with Aditxt for Mitomic diagnostic tests continues under September 2024 agreement.

## SEC filing metadata
- accession: 0001493152-25-018687
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315225018687/0001493152-25-018687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315225018687/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018687
- JSON: https://secwatch.observer/filing/0001493152-25-018687.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018687.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.